Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the art
about
Pharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancerFuture directions for bone metastasis research - highlights from the 2015 bone and the Oncologist new updates conference (BONUS)Immune regulation of bone metastasisCombination of the c-Met inhibitor tivantinib and zoledronic acid prevents tumor bone engraftment and inhibits progression of established bone metastases in a breast xenograft modelSystemic treatment approaches in her2-negative advanced breast cancer-guidance on the guidelinesEffects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases.Bone-immune cell crosstalk: bone diseases.Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone MetastasesDe-escalated administration of bone-targeted agents in patients with breast and prostate cancer-A survey of Canadian oncologists.Incidence, consequences and treatment of bone metastases in breast cancer patients-Experience from a single cancer centre.A systematic review of dosing frequency with bone-targeted agents for patients with bone metastases from breast cancer.Effects of de-escalated bisphosphonate therapy on the Functional Assessment of Cancer Therapy-Bone Pain, Brief Pain Inventory and bone biomarkers.Bone-targeted therapy for metastatic breast cancer-Where do we go from here? A commentary from the BONUS 8 meeting.Bone metastases in breast cancer: Frequency, metastatic pattern and non-systemic locoregional therapyCost implications of unwarranted imaging for distant metastasis in women with early-stage breast cancer in OntarioBone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment optionsA phase 2 trial exploring the clinical and correlative effects of combining doxycycline with bone-targeted therapy in patients with metastatic breast cancer.Extracellular vesicles in prostate cancer: new future clinical strategies?Pharmacotherapy of bone metastases in breast cancer patients--an update.Breast cancer and bone metastases: the association of axial skeleton MRI findings with skeletal-related events and survival.Skeletal Complications and Mortality in Thyroid Cancer: A Population-Based Study.Effects on bone resorption markers of continuing pamidronate or switching to zoledronic acid in patients with high risk bone metastases from breast cancer.Bone metastases in patients with small cell lung carcinoma: rate of development, early versus late onset, modality of treatment, and their impact on survival. A single-institution retrospective cohort study.Understanding the Progression of Bone Metastases to Identify Novel Therapeutic Targets.Oral surgery: The drug holiday.Quantitative contrast-enhanced CT attenuation evaluation of osseous metastases following chemotherapy.Physicians' preferences for bone metastases treatments in France, Germany and the United Kingdom.Efficacy and safety of de-escalation bone- modifying agents for cancer patients with bone metastases: a systematic review and meta-analysis
P2860
Q26746212-5FFE9493-31D4-4643-8548-7EF52F515864Q26747566-57E502AD-0A73-4400-8C66-69E7520860D4Q27005871-FBC65307-0218-4AF9-B17B-0E9A58446CD9Q27302940-49A1B0E1-80BA-4819-A55E-65ECA1CCD739Q28080469-28762880-3693-4E01-BF10-EEA502139F23Q34325491-83B47FC0-B56C-4BC4-8760-7EA230C99723Q35592362-52686D28-5F35-45FD-B07F-791E92A62313Q35750641-315615B5-0E1D-4CD6-B3F3-D5B3EE237542Q36491477-0D2CF349-336A-409F-9BD9-B7C72644F308Q36491533-D2D2749B-C18B-4DF3-8122-F066D8BCAAA0Q36491537-6FC37B8E-EBCC-4571-864D-3D931E3DD0E6Q36491554-FD072425-528E-4742-9172-F84F9E95A2F0Q36491642-E2888BA5-9814-470A-A5A2-7C05D567A7CAQ36492209-F99FA0A0-4043-4D3F-BFE7-D7166CFEC6BDQ36658816-E4F0F626-D82E-4D3E-860D-177F475CB412Q36798749-8060CFC6-3BDF-42F5-9A72-FD06430F521FQ37499970-3A5F3882-9DDD-4A5C-A3FF-F91AB06C6672Q37632337-E846ABA8-C655-407A-B3DB-8046C3F963C8Q38199759-BD7D6F88-BFCB-473F-85C5-ECACD639DC9FQ38227713-96B95557-961F-481F-9B0E-B6D84D71650CQ40282554-F37559E4-1889-4520-8814-5228E0984DEBQ47146433-8C3E326E-C663-4919-8C85-E590BD933351Q48719655-50968276-FA1D-49CC-9338-92659E7E7035Q49435928-719925D0-FE3C-4AF9-B60E-2F761BAB970AQ50061924-99BB5B41-45EC-4A88-916C-9EB361451962Q50551301-39F8249E-1159-470B-87E7-D066F666D83FQ55518625-B2DA9BD4-9710-4A4F-8C92-ACB3DB7434A0Q57071021-73B0332A-005A-4598-BF54-E95DC3A8255D
P2860
Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the art
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Bone-targeted agents and skele ...... tastases: the state of the art
@ast
Bone-targeted agents and skele ...... tastases: the state of the art
@en
type
label
Bone-targeted agents and skele ...... tastases: the state of the art
@ast
Bone-targeted agents and skele ...... tastases: the state of the art
@en
prefLabel
Bone-targeted agents and skele ...... tastases: the state of the art
@ast
Bone-targeted agents and skele ...... tastases: the state of the art
@en
P2093
P2860
P356
P1433
P1476
Bone-targeted agents and skele ...... tastases: the state of the art
@en
P2093
A H G Paterson
K A Gelmon
P2860
P304
P356
10.3747/CO.19.1011
P577
2012-10-01T00:00:00Z